IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update

What happened

IDEAYA Biosciences reported third-quarter 2026 results and said it completed a U.S. regulatory application submission for darovasertib plus crizotinib in metastatic uveal melanoma during the quarter. It also reported cash, cash equivalents and marketable securities at September 30, 2026, and maintained its cash runway guidance into 2030.

Confirmed

Global impact / market context

The completed application moves the drug combination into a regulatory review stage, but does not establish approval or sales. If approved, the treatment could add a revenue source; meanwhile, IDEAYA’s reported cash and unchanged runway guidance indicate its current operating plan is funded into 2030.

Analyst inference

The update combines a near-term regulatory milestone with earlier-stage research: IDEAYA also highlighted trial data for IDE849 and planned preclinical research presentations. Those programs could broaden future treatment opportunities, but their clinical and commercial value remains uncertain, while development continues to require company spending.

Analyst inference

What to watch

1. Watch for regulatory decisions and any disclosed timing for darovasertib plus crizotinib; approval would be needed before the combination could generate U.S. treatment sales. Analyst inference
2. IDEAYA expects initial results from its sponsored global Phase 1/2 IDE849 trial in the future; those data may clarify whether development should continue toward later testing. Confirmed
3. The company scheduled an R&D Day for November 16 to present preclinical combination research in KRAS-mutant cancers; later clinical testing would be needed to assess patient benefit. Confirmed

Evidence

• Original source link unavailable